FTC Challenges Illumina's $8B Deal For Cancer Detection Biz
The Federal Trade Commission on Tuesday moved to block biotechnology firm Illumina Inc.'s planned $8 billion acquisition of Grail Inc., a cancer-detection company it founded, over concerns about innovation....To view the full article, register now.
Already a subscriber? Click here to view full article